2Stanley F. Tolcapone:COMT inhibition for the treatment of Parkmson's disease. Neurology,1998;50 (Suppl 5):S1～S2
3Sage JI. Mark MH. Basic meehanisms of motor fluetuations. Neurology,1994:44(Suupl 6):S10～S14
4Maninez Martin P. Brien CF. Extending levodopa action:COMT inhibition. Neurology,1998;50(Suppl 6):S27～S32,discussion S44
5Rajput AH, Martin W, Saint Hllaire MH et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon:a double-blind, placeho-controlled,multi-center trial. Neurology,1997;49:1066～1071
6Matthias C, Kurth Charles H. COMT inhibition: A new treatment strategy for Parkinson's disease. Neurology,1998;50(Suppl 5) S3～S14
7Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibition of catechol-O-methyhmnsferase, Genpharmacol, 1994;25:813～824
8Dingemanse J, Jorga KM, Zutcher G et al. Pharmacokinetic-pharmacodynamic intraction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Pharmacol,1995:40:253～262
9Karin MC, Jorga. Pharmacokinetics,pharmacedynamics, and tolerability of tolcapone: A review of early studies in volunteers. Neurology,1998;50(Suppl 5): S31～S38
10Waters CH, Kurth M, Bailey P et al.Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment. Neurology, 1997:49:665～671
